HWA 285 (propentofylline)--a new compound for the treatment of both vascular dementia and dementia of the Alzheimer type.
The pharmacological profile of HWA 285 favors its use in patients with both Alzheimer's disease (PDD) and/or vascular dementia (MID). Clinical trials showed clinically relevant, statistically significant efficacy in the domains of cognitive function, global function and activities of daily living (ADL) in both PDD and MID. HWA 285 had a prolonged symptomatic effect for at least 12 months, although therapeutic effects were seen already after the first 3 months of treatment. HWA 285 was very well tolerated for at least 1 year.
Rother
M
M
HOECHST AG, HR PGU Cardiovascular Agents, Wiesbaden, Germany.
Kittner
B
B
Rudolphi
K
K
Rössner
M
M
Labs
K H
KH
D000203:Activities of Daily Living; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000503:physiopathology; D002545:Brain Ischemia / Q000188:drug therapy; D002986:Clinical Trials as Topic; D015140:Dementia, Vascular / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D016896:Treatment Outcome; D014970:Xanthines / Q000627:therapeutic use*
D014970:Xanthines; C032114:propentofylline